CGT Live

June 13, 2024

IN8bio’s Gamma-Delta T-cell Therapy INB-100 Helps Maintain Complete Remissions After HSCT in Patients With Hematologic Malignancies

Patients with hematologic malignancies treated with IN8bio’s INB-100, an allogeneic gamma-delta T-cell therapy, after receiving haploidentical stem cell transplant (HSCT) have maintained complete remissions (CRs) for over a year.1 The data, which comes from a phase 1 clinical trial (NCT03533816), were presented in a poster at the European Hematology Association (EHA) 2024 Congress, held June 13 to 16, both virtually and in Madrid, Spain.